Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26263
Title: Medical imaging and nuclear medicine: a Lancet Oncology Commission.
Austin Authors: Hricak, Hedvig;Abdel-Wahab, May;Atun, Rifat;Lette, Miriam Mikhail;Paez, Diana;Brink, James A;Donoso-Bach, Lluís;Frija, Guy;Hierath, Monika;Holmberg, Ola;Khong, Pek-Lan;Lewis, Jason S;McGinty, Geraldine;Oyen, Wim J G;Shulman, Lawrence N;Ward, Zachary J;Scott, Andrew M 
Affiliation: Department of Global Health and Population, Harvard TH Chan School of Public Health, Boston, MA, USA
Department of Global Health and Social Medicine, Harvard Medical School, Harvard University, Boston, MA, USA
International Atomic Energy Agency, Division of Human Health, Vienna, Austria
Radiation Oncology, National Cancer Institute, Cairo University, Cairo, Egypt
Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
Departments of Radiology and Population Science, Weill Cornell Medical College, New York, NY, USA
American College of Radiology, Reston, VA, USA
Department of Radiology and Molecular Pharmacology Programme, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Departments of Pharmacology and Radiology, Weill Cornell Medical College, New York, NY, USA
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Department of Radiology, Weill Cornell Medical College, New York, NY, USA
Department of Biomedical Sciences and Humanitas Clinical and Research Centre, Department of Nuclear Medicine, Humanitas University, Milan, Italy; Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, Netherlands
Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, Nijmegen, Netherlands
Olivia Newton-John Cancer Research Institute
Molecular Imaging and Therapy
School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia
Department of Medicine, University of Melbourne, Melbourne, VIC, Australia
Center for Health Decision Science, Harvard TH Chan School of Public Health, Boston, MA, USA
Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Harvard University, Boston, MA, USA
International Atomic Energy Agency, Division of Human Health, Vienna, Austria
Department of Medical Imaging, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain
Université de Paris, Paris, France
European Society of Radiology, Vienna, Austria
Radiation Protection of Patients Unit, International Atomic Energy Agency, Vienna, Austria
Department of Diagnostic Radiology, University of Hong Kong, Hong Kong Special Administrative Region, China
Issue Date: Apr-2021
metadata.dc.date: 2021-03-04
Publication information: The Lancet. Oncology 2021; 22(4): e136-e172
Abstract: The diagnosis and treatment of patients with cancer requires access to imaging to ensure accurate management decisions and optimal outcomes. Our global assessment of imaging and nuclear medicine resources identified substantial shortages in equipment and workforce, particularly in low-income and middle-income countries (LMICs). A microsimulation model of 11 cancers showed that the scale-up of imaging would avert 3·2% (2·46 million) of all 76·0 million deaths caused by the modelled cancers worldwide between 2020 and 2030, saving 54·92 million life-years. A comprehensive scale-up of imaging, treatment, and care quality would avert 9·55 million (12·5%) of all cancer deaths caused by the modelled cancers worldwide, saving 232·30 million life-years. Scale-up of imaging would cost US$6·84 billion in 2020-30 but yield lifetime productivity gains of $1·23 trillion worldwide, a net return of $179·19 per $1 invested. Combining the scale-up of imaging, treatment, and quality of care would provide a net benefit of $2·66 trillion and a net return of $12·43 per $1 invested. With the use of a conservative approach regarding human capital, the scale-up of imaging alone would provide a net benefit of $209·46 billion and net return of $31·61 per $1 invested. With comprehensive scale-up, the worldwide net benefit using the human capital approach is $340·42 billion and the return per dollar invested is $2·46. These improved health and economic outcomes hold true across all geographical regions. We propose actions and investments that would enhance access to imaging equipment, workforce capacity, digital technology, radiopharmaceuticals, and research and training programmes in LMICs, to produce massive health and economic benefits and reduce the burden of cancer globally.
URI: https://ahro.austin.org.au/austinjspui/handle/1/26263
DOI: 10.1016/S1470-2045(20)30751-8
PubMed URL: 33676609
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

14
checked on Jul 2, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.